[NFS-02] Neuroscience Frontier Symposium 02
Original discovery and therapy for SCA from Japan to the world

[NFS-02-1] Pathogenesis of spinocerebellar ataxia type 31 (SCA31)

^○Kinya Ishikawa¹, Miwa Higashi², Michi Okita¹, Hanako Aoki², Meiko Asaka³, Taro Ishiguro², Nozomu Sato², Yoshitaka Nagai⁴, Dai Yanagihara³, Takanori Yokota² (1.The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University, Japan, 2.Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Japan, 3.Graduate School of Arts and Sciences, the University of Tokyo, Japan, 4.Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Japan)

Spinocerebellar ataxia (SCA) is neurodegenerative diseases affecting mainly cerebellum and brainstem, and new subtypes and pathologies of SCAs have been continuously discovered in the world. Especially, SCA31 and SCA36 (nicknamed Asidan) were first found in Japanese, and their clinical and pathological features are quite unique compared with other SCAs. Recent discovery of repeat associated non-ATG (RAN) translation in the pathogenesis of hereditary SCAs carrying repeat expansion mutations has tremendously extended our understanding in the pathogenesis of SCA and other neurodegenerative diseases. Furthermore, the development of new therapy for SCAs have been extensively investigated in Japan and the world. The aim of this symposium is to learn and discuss the current clinical, pathological and therapeutic findings of SCAs for Japanese and Asian neurologists and neuroscientists.

1989 Graduated from the University of Tsukuba, Medical School.
1999 Assistant Professor, Department of Neurology, Tokyo Medical and Dental University
(Professor Hidehiro Mizusawa)
2003 Junior Associate Professor, Department of Neurology, Tokyo Medical and Dental University
2015 Professor, Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University